相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders
Satoru Noji et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials
Feng Huang et al.
CLINICAL RHEUMATOLOGY (2019)
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms
Min Hu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis
Steven H. Spergel et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Transforming growth factor 1 promotes migration and invasion in HepG2 cells: Epithelial-to-mesenchymal transition via JAK/STAT3 signaling
Xiao-Long Lin et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2018)
Identification of N-{cis-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminolcyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Michael L. Vazquez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier et al.
BMC RHEUMATOLOGY (2018)
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
Stephen Hall et al.
RHEUMATOLOGY AND THERAPY (2018)
Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway
Liu-Ya Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules
Ana S. Newton et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis
Debomita Chakraborty et al.
NATURE COMMUNICATIONS (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Silvio Danese et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2016)
Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells
Yuan-Jing Gu et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3
Yutaka Nakajima et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Alejandro V. Villarino et al.
JOURNAL OF IMMUNOLOGY (2015)
THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib
R. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Christel J. Menet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
Hajime Akada et al.
STEM CELLS (2014)
Profound Methyl Effects in Drug Discovery and a Call for New C-H Methylation Reactions
Heike Schoenherr et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Transforming Growth Factor-β (TGF-β)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation
Yan Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Nilda L. Alicea-Velazquez et al.
CURRENT DRUG TARGETS (2011)
The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Ursula A. White et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6
Jill E. Chrencik et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Novel procedure for modeling ligand/receptor induced fit effects
W Sherman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Development and application of high throughput plasma stability assay for drug discovery
L Di et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry
MJ Kim et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
Experimental design on single-time-point high-throughput microsomal stability assay
L Di et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
分享论文
